Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
Novartis |
---|---|
Information provided by: | Novartis |
ClinicalTrials.gov Identifier: | NCT00171327 |
Patients with mild to moderate hypertension, dyslipidemia (imbalanced blood lipids) and decreased vascular dilatation, receiving a cholesterol lowering diet were given either valsartan or fluvastatin for 8 weeks. At week 8 all patients were administered a combination treatment with valsartan 160 mg and fluvastatin 80 mg.
Condition | Intervention | Phase |
---|---|---|
Hypertension Dyslipidemia |
Drug: valsartan, fluvastatin |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Open Label, Uncontrolled, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Efficacy and Safety of Fluvastatin 80 mg or Valsartan 160 mg and Their Combination in Dyslipidemic Patients With Arterial Hypertension and Endothelial Dysfunction |
Estimated Enrollment: | 100 |
Study Start Date: | July 2004 |
Ages Eligible for Study: | 30 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Other inclusion and exclusion criteria may apply
Study ID Numbers: | CXUO320BRU01 |
Study First Received: | September 12, 2005 |
Last Updated: | March 20, 2008 |
ClinicalTrials.gov Identifier: | NCT00171327 |
Health Authority: | Russia: Pharmacological Committee, Ministry of Health |
arterial hypertension dyslipidemia valsartan fluvastatin |
Metabolic Diseases Vascular Diseases Metabolic disorder Valsartan |
Fluvastatin Dyslipidemias Lipid Metabolism Disorders Hypertension |
Antimetabolites Molecular Mechanisms of Pharmacological Action Therapeutic Uses Antilipemic Agents Enzyme Inhibitors Cardiovascular Diseases |
Cardiovascular Agents Anticholesteremic Agents Antihypertensive Agents Hydroxymethylglutaryl-CoA Reductase Inhibitors Pharmacologic Actions |